OHSU

IRB #

IRB00009480

Title

A Randomized, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer

Principal Investigator

Matthew Taylor

Study Purpose

To compare the effects of selumetinib (study drug) with radioactive iodine (RAI) therapy versus placebo and RAI therapy in adults with differentiated thyroid cancer.

Medical Condition(s)

Differentiated Thyroid Cancer

Eligibility Criteria

1. Adults aged 18 years or above.
2. Confirmed diagnosis of differentiated thyroid cancer.
3. Had a one- or two-stage total thyroidectomy (all known tumor must have been resected).
4. Must be suitable for RAI therapy and thyroid stimulating hormone (TSH) suppression.
5. Be willing to start treatment within 16 weeks of cancer surgery.
6. Other criteria apply.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

3 years

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

AstraZeneca AB

Recruitment End

03/01/2016

Compensation Provided

No


Go Back